• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].

作者信息

Fleckenstein A, Frey M, Fleckenstein-Grün G

出版信息

Fortschr Med. 1984 Jul 26;102(27-28):713-7.

PMID:6479813
Abstract

One of the most important effects of the new pharmacological family of Ca-antagonistic drugs is the prevention of deleterious myocardial Ca overload which is the decisive etiological factor in the production of cardiac necroses, as for instance b-adrenergic overstimulation. However, at an advanced age, also in the human arterial walls, cytotoxic degrees of Ca overload are reached, which probably play an important role in the pathogenesis of arteriosclerotic lesions. It is interesting that severe diabetics and heavy smokers exhibit a much faster progression of age-dependent arterial calcinosis than normal human subjects. In rats the Ca antagonists verapamil and diltiazem not only prevented arterial calcinosis due to overdoses of vitamin D and dihydrotachysterol, but also counteracted age-dependent Ca accumulation. Most impressive effects were also obtained in spontaneously hypertensive rats; chronic oral treatment with nifedipine and other 1,4-dihydropyridines as well as with verapamil kept both blood pressure and Ca content of the arterial walls (aorta, A. mesenterica) in the normal range. Our findings nourish the hope that suitable Ca antagonists can possibly interfere with arterial calcinosis also in humans, thus bearing a new vasoprotective indication.

摘要

相似文献

1
[Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
Fortschr Med. 1984 Jul 26;102(27-28):713-7.
2
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
J Cardiovasc Pharmacol. 1994;24 Suppl 2:S75-84.
3
Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists.
J Cardiovasc Pharmacol. 1991;18 Suppl 6:S1-9.
4
Mechanism of action of calcium antagonists in heart and vascular smooth muscle.钙拮抗剂在心脏和血管平滑肌中的作用机制。
Eur Heart J. 1988 Jun;9 Suppl H:95-9. doi: 10.1093/eurheartj/9.suppl_h.95.
5
Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.钙拮抗剂用于动脉高血压长期治疗的实验依据。
Am J Cardiol. 1985 Dec 6;56(16):3H-14H. doi: 10.1016/0002-9149(85)90537-5.
6
History of calcium antagonists.钙拮抗剂的历史。
Circ Res. 1983 Feb;52(2 Pt 2):I3-16.
7
Experimental vasoprotection by a novel erythrocyte-derived depressing factor in rats with arterial calcinosis.
Vascul Pharmacol. 2009 Jan-Feb;50(1-2):65-70. doi: 10.1016/j.vph.2008.10.001. Epub 2008 Nov 1.
8
[Calcification of the arterial wall in the aging process. Electron microscopic and biochemical studies of a model of vitamin D3 overdose].[衰老过程中动脉壁的钙化。维生素D3过量模型的电子显微镜和生化研究]
Aktuelle Gerontol. 1983 May;13(3):115-8.
9
Protective effects of various calcium antagonists against experimental arteriosclerosis.
J Hum Hypertens. 1992 Dec;6 Suppl 1:S13-8.
10
Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.钙拮抗剂在动脉硬化进展中的作用。来自动物实验和临床经验的证据。第二部分。钙通道阻滞剂对动脉粥样硬化性冠状动脉疾病预防作用的临床经验。
Basic Res Cardiol. 1994;89 Suppl 1:177-84.